HC Wainwright Has Bearish Estimate for ONCY FY2026 Earnings

Oncolytics Biotech Inc. (NASDAQ:ONCY) – HC Wainwright dropped their FY2026 earnings per share (EPS) estimates for shares of Oncolytics Biotech in a research report issued to clients and investors on Wednesday, August 19th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings of ($0.30) per share for the year, down from their previous forecast of ($0.28). HC Wainwright currently has a “Buy” rating and a $5.00 target price on the stock. The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.25) per share. HC Wainwright also issued estimates for Oncolytics Biotech’s Q4 2026 earnings at ($0.07) EPS, Q2 2027 earnings at ($0.05) EPS, Q3 2027 earnings at ($0.05) EPS, Q4 2027 earnings at ($0.06) EPS, FY2027 earnings at ($0.21) EPS, FY2028 earnings at ($0.19) EPS, FY2029 earnings at ($0.19) EPS and FY2030 earnings at $0.00 EPS.

Oncolytics Biotech (NASDAQ:ONCY) last issued its earnings results on Wednesday, August 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.03).

ONCY has been the subject of several other reports. Weiss Ratings upgraded shares of Oncolytics Biotech from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, July 13th. Wall Street Zen lowered shares of Oncolytics Biotech from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $5.00.

Oncolytics Biotech Stock Performance

NASDAQ ONCY opened at $0.80 on Friday. The firm has a market capitalization of $102.23 million, a price-to-earnings ratio of -2.36 and a beta of 1.13. Oncolytics Biotech has a one year low of $0.73 and a one year high of $1.51. The company’s 50 day moving average price is $0.86 and its 200 day moving average price is $0.92.

Hedge Funds Weigh In On Oncolytics Biotech

Several hedge funds and other institutional investors have recently bought and sold shares of ONCY. Scientech Research LLC purchased a new position in Oncolytics Biotech in the 3rd quarter worth approximately $25,000. Vantage Point Financial LLC purchased a new stake in shares of Oncolytics Biotech during the second quarter valued at approximately $28,000. Blair William & Co. IL purchased a new stake in shares of Oncolytics Biotech during the fourth quarter valued at approximately $28,000. Security National Bank of Sioux City Iowa IA acquired a new position in shares of Oncolytics Biotech during the fourth quarter worth $29,000. Finally, Ground Swell Capital LLC acquired a new position in shares of Oncolytics Biotech during the fourth quarter worth $30,000. 6.82% of the stock is owned by institutional investors and hedge funds.

More Oncolytics Biotech News

Here are the key news stories impacting Oncolytics Biotech this week:

• Positive Sentiment: Oncolytics Biotech gained FDA alignment on its REO 033 trial, potentially reducing regulatory uncertainty and supporting the development path for its oncology candidate. Oncolytics Biotech gains FDA alignment on REO 033 trial
• Positive Sentiment: HC Wainwright maintained its Buy rating and a $5.00 price target. Based on the referenced $0.80 share price, the target indicates substantial potential upside, although it remains dependent on successful clinical and commercial execution. HC Wainwright Lowers Oncolytics Biotech Price Target to $5.00
• Neutral Sentiment: ONCY opened at $0.80, below its 50-day and 200-day moving averages of $0.86 and $0.92, respectively, and near its 52-week low of $0.73. This reflects weak recent trading momentum despite the analyst’s bullish rating.
• Negative Sentiment: HC Wainwright reduced its EPS forecasts across multiple periods: FY2026 to a loss of $0.30 from $0.28, FY2027 to a loss of $0.21 from $0.15, FY2028 to a loss of $0.19 from $0.14, FY2029 to a loss of $0.19 from $0.12, and FY2030 to breakeven from projected earnings of $0.14. Quarterly estimates for Q4 2026, Q2 2027, Q3 2027 and Q4 2027 were also lowered.
• Negative Sentiment: The estimate revisions suggest analysts expect slower profitability improvement and continued cash-burn risk. Oncolytics previously reported a quarterly loss of $0.08 per share, worse than the $0.05 consensus estimate, while the broader current-year consensus remains a loss of $0.25 per share.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc (NASDAQ: ONCY) is a clinical-stage biotechnology company focused on the development of novel oncolytic viral therapies for the treatment of cancer. The company’s lead investigational agent, pelareorep (Reolysin), is a proprietary formulation of reovirus engineered to selectively infect and destroy tumor cells while stimulating a systemic antitumor immune response. Oncolytics leverages the natural biology of the virus to enhance the activity of standard‐of‐care treatments and immune checkpoint inhibitors.

Pelareorep has progressed into multiple advanced clinical trials, with combination studies conducted in metastatic breast cancer, non‐small cell lung cancer and head and neck cancers.